BUZZ-H.C. Wainwright starts coverage of ImmunityBio with 'buy' rating

Reuters

Mar 06

** Brokerage H.C. Wainwright starts coverage on cancer therapy maker ImmunityBio IBRX.O with "buy" rating and $8 PT; represents 161% upside to the stock's last close

** Brokerage says co is expected to see "compelling growth opportunity for 2025" in its bladder cancer therapy, Anktiva; estimates $4.3 bln in sales by 2034

** Believes Anktiva can be a "backbone therapy" with a wide range of applications, but its value is "highly underappreciated"

** Anktiva + BCG vaccine achieved the highest complete response rate, 62%, outperforming competitors like Merck's MRK.N Keytruda and Ferring's Adstiladrin - Brokerage

** Last month, FDA authorized co's new version of the BCG vaccine to treat bladder clancer

** IBRX fell ~51% in 2024

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2517563661"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2517563661\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2517563661?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-06 19:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2517563661","market":"us","top_or_hot":-1,"title":"BUZZ-H.C. Wainwright starts coverage of ImmunityBio with 'buy' rating","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-H.C. Wainwright starts coverage of ImmunityBio with 'buy' rating</title></head><body><p>** Brokerage H.C. Wainwright starts coverage on <span>cancer therapy maker </span>ImmunityBio <span>IBRX.O</span> with \"buy\" rating and $8 PT; represents 161% upside to the stock's last close</p><p>** Brokerage says co is expected to see \"compelling growth opportunity for 2025\" in its bladder cancer therapy, Anktiva<span>; estimates</span> $4.3 bln in sales by 2034</p><p>** Believes Anktiva <span>can </span>be a \"backbone therapy\" with a wide range of applications, but its value is \"highly underappreciated\"</p><p>** Anktiva + BCG <span>vaccine </span>achieved the highest complete response rate, 62%, outperforming competitors like Merck's <span>MRK.N</span> Keytruda and Ferring's Adstiladrin - Brokerage</p><p>** Last month, FDA <span>authorized</span> co's new version of the BCG vaccine <span>to treat bladder clancer</span></p><p>** IBRX fell ~51% in 2024</p><p> (Reporting by Kamal Choudhury in Bengaluru)</p><p> ((Kamal.Choudhury@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-H.C. Wainwright starts coverage of ImmunityBio with 'buy' rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-H.C. Wainwright starts coverage of ImmunityBio with 'buy' rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-03-06 19:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-H.C. Wainwright starts coverage of ImmunityBio with 'buy' rating</title></head><body><p>** Brokerage H.C. Wainwright starts coverage on <span>cancer therapy maker </span>ImmunityBio <span>IBRX.O</span> with \"buy\" rating and $8 PT; represents 161% upside to the stock's last close</p><p>** Brokerage says co is expected to see \"compelling growth opportunity for 2025\" in its bladder cancer therapy, Anktiva<span>; estimates</span> $4.3 bln in sales by 2034</p><p>** Believes Anktiva <span>can </span>be a \"backbone therapy\" with a wide range of applications, but its value is \"highly underappreciated\"</p><p>** Anktiva + BCG <span>vaccine </span>achieved the highest complete response rate, 62%, outperforming competitors like Merck's <span>MRK.N</span> Keytruda and Ferring's Adstiladrin - Brokerage</p><p>** Last month, FDA <span>authorized</span> co's new version of the BCG vaccine <span>to treat bladder clancer</span></p><p>** IBRX fell ~51% in 2024</p><p> (Reporting by Kamal Choudhury in Bengaluru)</p><p> ((Kamal.Choudhury@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IBRX","symbol_name":"ImmunityBio, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nL3N3PP0XQ:1","article_id":"2517563661","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2517563661","pubTimestamp":1741262170,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-H.C. Wainwright starts coverage of ImmunityBio with 'buy' rating** Brokerage H.C. Wainwright starts coverage on cancer therapy maker ImmunityBio IBRX.O with \"buy\" rating and $8 PT; represents 161% upside to the stock's last close** Brokerage says co is expected to see \"compelling growth opportunity for 2025\" in its bladder cancer therapy, Anktiva; estimates $4.3 bln in sales by 2034** Believes Anktiva can be a \"backbone therapy\" with a wide range of applications, but its value is \"highly underappreciated\"** Anktiva + BCG vaccine achieved the highest complete response rate, 62%, outperforming competitors like Merck's MRK.N Keytruda and Ferring's Adstiladrin - Brokerage** Last month, FDA authorized co's new version of the BCG vaccine to treat bladder clancer** IBRX fell ~51% in 2024  ","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"IBRX":"ImmunityBio, Inc.","MRK":"默沙东"},"translate_title":"巴斯-H.C。Wainwright开始对ImmunityBio给予“买入”评级","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRK":0.9,"IBRX":0.9},"content_text":"BUZZ-H.C. Wainwright starts coverage of ImmunityBio with 'buy' rating** Brokerage H.C. Wainwright starts coverage on cancer therapy maker ImmunityBio IBRX.O with \"buy\" rating and $8 PT; represents 161% upside to the stock's last close** Brokerage says co is expected to see \"compelling growth opportunity for 2025\" in its bladder cancer therapy, Anktiva; estimates $4.3 bln in sales by 2034** Believes Anktiva can be a \"backbone therapy\" with a wide range of applications, but its value is \"highly underappreciated\"** Anktiva + BCG vaccine achieved the highest complete response rate, 62%, outperforming competitors like Merck's MRK.N Keytruda and Ferring's Adstiladrin - Brokerage** Last month, FDA authorized co's new version of the BCG vaccine to treat bladder clancer** IBRX fell ~51% in 2024 (Reporting by Kamal Choudhury in Bengaluru) ((Kamal.Choudhury@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}